VJHemOnc is committed to improving our service to you

ASH 2019 | Long-term ibrutinib outcomes vs. prior regimens: pooled analysis in R/R MCL

VJHemOnc is committed to improving our service to you

Simon Rule

Simon Rule, MD, Plymouth University, Plymouth, UK, outlines data from a pooled analysis of ibrutinib in relapsed/refractory (R/R) mantle cell lymphoma (MCL) with extended follow-up up to 7.5 years and a comparison of outcomes with ibrutinib versus the prior regimens. Prof. Rule considers that the key message from this analysis is that ibrutinib should be used at first relapsed, even in patients that get the best response to chemotherapy. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter